NEWS
Direct granting support of Protein Alternatives’ Seal of Excellence project by Community of Madrid
November 21st, 2023 ProAlt’s therapeutic project named ‘METASTCURE' that has obtained the ‘Seal of Excellence’ label within the Accelerator program of the European Innovation Council has been selected by the Community of Madrid for direct-grant support. The excellence, impact and remarkable potential for success of METASCURE project made it eligible to receive a substantial grant [...]
ProAlt’s project for development of anti-CDH17 second-generation antibodies receives funding from CDTI
January 27th, 2023 The collaborative project named ‘Preclinical development and evolution of second-generation antibodies for the treatment of metastatic colorectal cancer’ has been selected to receive funding in the joint ISCIII-CDTI call for proposals in innovation linked to ‘Personalized Medicine and Advanced Therapies’. The multidisciplinary research consortium involves strategic partners like the Group of Mechanisms [...]
CANCERKINE project receives funding from the Ministry of Science and Innovation
The project named CANCERKINE and title ‘Preclinical development of monoclonal antibodies against IL13Ra2 for cancer therapy’ has been selected to receive funding from the Ministry of Science and Innovation. The aim of CANCERKINE is the preclinical development of the anti-IL13Ra2 monoclonal antibody 5.5.4 and their by-products in order to further advance this biological therapeutic product [...]
PROALT selected by the European Innovation Council to pitch at the EIC Investor Day with CUF
PROALT has been selected by the European Innovation Council (EIC) to pitch its innovative therapeutic solutions in oncology to top European investors at the EIC Investor Day with CUF. The event took place in Lisbon (Portugal) on 29 and 30 November 2022, where the Company has presented in the ‘Biotech & Pharmaceuticals session’ its antibodies [...]
PROALT participates in Anglonordic Life Science Conference 2022
Anti-CDH17 and anti-IL13Ra2 monoclonal antibodies developed by PROALT togheter with the Spanish Research Council (CSIC) are promising novel biological drugs to treat metastatic colorectal cancer (mCRC) and glioblastoma (GBM). Both could be new options for people whose cancers have not responded to previous lines of treatment. Delegates and Investors at the Anglonordic Life Science Conference [...]
